These challenges and key action items to overcome them are described in an article published on Fast Track as part of the World Stem Cell Report 2013, a special upcoming supplement to Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website.
The World Stem Cell Report is the official publication of the World Stem Cell Summit 2013, to be held December 4-6, 2013 in San Diego, CA. More than 1,000 researchers and clinicians from around the globe will attend the Summit.
In the article “Key Action Items for the Stem Cell Field Looking to 2014,” author Paul S. Knoepfler, University of California Davis School of Medicine, describes the building momentum behind stem cells, both for their impact as transformative basic science discoveries and their potential for translation to clinical medicine. At the same time, however, he outlines several critical challenges, including “stem cell tourism,” the complex balance between innovation and regulatory/FDA compliance, and the need to educate physicians and patients about stem cell therapies.
“Paul Knoepfler is being honored at the World Stem Cell Summit with the Stem Cell Action ‘National Advocacy Award’ from the Genetics Policy Institute,” says Bernard Siegel, JD, Co-Chair of the 2013 World Stem Cell Summit and Executive Director, Genetics Policy Institute (GPI, Palm Beach, FL). Siegel is also Co-Editor-in-Chief of the World Stem Cell Report. “Dr. Knoepfler’s unique perspective as a scientist and patient advocate provides a fresh perspective to the stem cell universe. As a communicator, Paul is unsurpassed. We are proud to include his views in the Report.”
“Key opinion leaders in the field like Paul Knoepfler bring into focus where we are, and where we are not yet, in regard to the further translation of stem cell research,” says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine (Detroit, MI).
The World Stem Cell Summit is the flagship meeting of the international stem cell community. The Summit aims to accelerate the discovery and development of lifesaving cures and therapies, bringing global stakeholders together to solve global challenges. It builds a foundation to advance cell therapies by establishing a supportive environment of regulation, legislation, financing, reimbursement, and patient advocacy. The 2013 World Stem Cell Summit will be held at the Manchester Grand Hyatt San Diego, in San Diego, California, December 4-6, 2013. It is presented by GPI and is co-organized by the California Institute for Regenerative Medicine, Mayo Clinic, Scripps Research Institute, Sanford-Burnham Medical Research Institute, and Kyoto University Institute for Integrated Cell-Material Sciences (iCeMS). For more information, visit the World Stem Cell Summit website.
The Genetics Policy Institute supports stem cell research to develop therapeutics and cures. GPI pursues its mission by producing the World Stem Cell Summit, honoring community leaders through the Stem Cell Action Awards, publishing the World Stem Cell Report, organizing educational initiatives and fostering strategic collaborations. For more information about GPI, click here.
Mary Ann Liebert, Inc., publishers and Genetic Engineering & Biotechnology News (GEN), a Liebert publication, are joint platinum media sponsors of the 2013 World Stem Cell Summit.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year online with Open Access options and in print. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. Complete tables of content and a sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website. – See more at: http://news.ualberta.ca/newsarticles/2013/october/ualberta-medical-researchers-discover-potential-new-treatment-for-colitis?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+UofAExpressNewsArticles+%28University+of+Alberta+News%29#sthash.5RLpzRaZ.dpuf